Clinical trial · Interventional
Evaluation of CG-100 Intraluminal Bypass Device
NCT05632744CI-TRIAL-00116687completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation of CG-100 Intraluminal Bypass device
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CG-100 Intraluminal Bypass Device | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CG-100 Intraluminal Bypass Device
- description
- Subjects will be treated with CG-100 Intraluminal Bypass Device
- interventionNames
- Device: CG-100 Intraluminal Bypass Device
Primary outcomes (1)
- measure
- Safety of the CG-100 Intraluminal Bypass Device
- timeFrame
- 10 days
- description
- Assessment of Serious Adverse Events
Secondary outcomes (1)
- measure
- Safety of the CG-100 Intraluminal Bypass Device
- timeFrame
- 4 weeks
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 22 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria (pre-operative): 1. Willing to comply with protocol-specified follow-up evaluations 2. 22-75 (inclusive) years of age at screening 3. Diagnosed with colorectal cancer 4. Has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.